相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer
Francesco Morra et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
State-of-the-art strategies for targeting the DNA damage response in cancer
Patrick G. Pilie et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
CCDC6: the identity of a protein known to be partner in fusion
Aniello Cerrato et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy
Kenneth M. Felsenstein et al.
NATURE REVIEWS UROLOGY (2018)
An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations
Nicholas Pulliam et al.
CLINICAL CANCER RESEARCH (2018)
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
Min Yuen Teo et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Immune checkpoint therapy in liver cancer
Feng Xu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
Manish R. Patel et al.
LANCET ONCOLOGY (2018)
Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy
Thiru Prasanna et al.
CANCER SCIENCE (2018)
Development of PARP and Immune-Checkpoint Inhibitor Combinations
Ross A. Stewart et al.
CANCER RESEARCH (2018)
Combining DNA damaging therapeutics with immunotherapy: more haste, less speed
Jessica S. Brown et al.
BRITISH JOURNAL OF CANCER (2018)
Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
Eileen E. Parkes et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
Eileen E. Parkes et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Padmanee Sharma et al.
LANCET ONCOLOGY (2017)
Epigenetics and immunotherapy: The current state of play
Jennifer Dunn et al.
MOLECULAR IMMUNOLOGY (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
RAD51 interconnects between DNA replication, DNA repair and immunity
Souparno Bhattacharya et al.
NUCLEIC ACIDS RESEARCH (2017)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope
Jonathan M. Lehman et al.
CURRENT ONCOLOGY REPORTS (2017)
DNA Damage and Repair Biomarkers of Immunotherapy Response
Kent W. Mouw et al.
CANCER DISCOVERY (2017)
The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells
Francesco Morra et al.
ONCOTARGET (2017)
No patient left behind: The promise of immune priming with epigenetic agents
Corey A. Carter et al.
ONCOIMMUNOLOGY (2017)
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma Updated Results From a Phase 1/2 Open-label Study
Thomas Powles et al.
JAMA ONCOLOGY (2017)
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Shiping Jiao et al.
CLINICAL CANCER RESEARCH (2017)
The Emerging Role of Homologous Recombination Repair and PARP Inhibitors in Genitourinary Malignancies
Kalen J. Rimar et al.
CANCER (2017)
PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations
T. Helleday
ANNALS OF ONCOLOGY (2016)
Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer
Nidal E. Muvarak et al.
CANCER CELL (2016)
Combining Epigenetic and Immunotherapy to Combat Cancer
Katherine B. Chiappinelli et al.
CANCER RESEARCH (2016)
Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach
Qingdi Quentin Li et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Trends and advances in tumor immunology and lung cancer immunotherapy
Mohanad Aldarouish et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2016)
Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic
Aniello Cerrato et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2016)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al.
LANCET (2016)
A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells
D. S. Das et al.
LEUKEMIA (2016)
Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
Yi Du et al.
NATURE MEDICINE (2016)
Emerging role of immunotherapy in urothelial carcinoma-Advanced disease
Matthew Zibelman et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2016)
A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance
Raphael Ceccaldi et al.
CANCER RESEARCH (2015)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts
David Roulois et al.
CELL (2015)
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Katherine B. Chiappinelli et al.
CELL (2015)
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
Geoffrey Kim et al.
CLINICAL CANCER RESEARCH (2015)
Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy
Michele Maio et al.
CLINICAL CANCER RESEARCH (2015)
Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer
Elizabeth R. Plimack et al.
EUROPEAN UROLOGY (2015)
DNA Damage Primes the Type I Interferon System via the Cytosolic DNA Sensor STING to Promote Anti-Microbial Innate Immunity
Anetta Hartlova et al.
IMMUNITY (2015)
Structures and Mechanisms of Enzymes Employed in the Synthesis and Degradation of PARP-Dependent Protein ADP-Ribosylation
Eva Barkauskaite et al.
MOLECULAR CELL (2015)
Targeting the DNA Damage Response in Cancer
Mark J. O'Connor
MOLECULAR CELL (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity
Hongjuan Zhao et al.
ONCOTARGET (2015)
FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC
Francesco Morra et al.
ONCOTARGET (2015)
The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent
Jan Scicinski et al.
Redox Biology (2015)
New therapeutic perspectives in CCDC6 deficient lung cancer cells
Francesco Morra et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
STING: infection, inflammation and cancer
Glen N. Barber
NATURE REVIEWS IMMUNOLOGY (2015)
Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage
Weiguo Jian et al.
ANTI-CANCER DRUGS (2014)
Decitabine Induces Delayed Reactive Oxygen Species (ROS) Accumulation in Leukemia Cells and Induces the Expression of ROS Generating Enzymes
Tamer E. Fandy et al.
CLINICAL CANCER RESEARCH (2014)
Comprehensive molecular characterization of urothelial bladder carcinoma
John N. Weinstein et al.
NATURE (2014)
Mechanisms underlying mutational signatures in human cancers
Thomas Helleday et al.
NATURE REVIEWS GENETICS (2014)
The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2′-deoxycytidine lesions
Manuel Luis Orta et al.
NUCLEIC ACIDS RESEARCH (2014)
Epigenetic drugs as immunomodulators for combination therapies in solid tumors
Luca Sigalotti et al.
PHARMACOLOGY & THERAPEUTICS (2014)
Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition
Junko Murai et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Critical role of CCDC6 in the neoplastic growth of testicular germ cell tumors
Stefania Staibano et al.
BMC CANCER (2013)
Potential of the Synthetic Lethality Principle
Sebastian M. B. Nijman et al.
SCIENCE (2013)
The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art
Mike De Vos et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor Cells
Hsing-Chen Tsai et al.
CANCER CELL (2012)
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai et al.
CANCER RESEARCH (2012)
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Suzanne L. Topalian et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
The DNA damage response and cancer therapy
Christopher J. Lord et al.
NATURE (2012)
Loss of CCDC6, the First Identified RET Partner Gene, Affects pH2AX S139 Levels and Accelerates Mitotic Entry upon DNA Damage
Francesco Merolla et al.
PLOS ONE (2012)
New Therapeutic Challenges in Advanced Bladder Cancer
Joaquim Bellmunt et al.
SEMINARS IN ONCOLOGY (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder
Yaoting Gui et al.
NATURE GENETICS (2011)
The DNA Damage Response: Making It Safe to Play with Knives
Alberto Ciccia et al.
MOLECULAR CELL (2010)
Molecular origins of cancer: Epigenetics in cancer
Manel Esteller
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Epigenetic control of the immune escape mechanisms in malignant carcinomas
A. Francesca Setiadi et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Chromatin modifications and their function
Tony Kouzarides
CELL (2007)
Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines.
C Stresemann et al.
CANCER RESEARCH (2006)
5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal
K Ghoshal et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Hallmarks of 'BRCAness' in sporadic cancers
N Turner et al.
NATURE REVIEWS CANCER (2004)
分享论文
